[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606445":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":60,"collaborators":11,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":11,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":11,"overallStatus":82,"whyStopped":11,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Methylprednisolone group","EXPERIMENTAL",null,[13],"Drug: Methylprednisolone sodium succinate",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo group","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Methylprednisolone sodium succinate","Intravenous methylprednisolone sodium succinate will be administered at a dose of 2 mg\u002Fkg\u002Fday for 3 days, with a maximum daily dose of 160 mg (4 vials, 40 mg\u002Fvial).\n\nIt is recommended that the initial dose be administered as soon as possible after randomization.",[9],[26],"Methylprednisolone",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"Placebo","Matched intravenous placebo will be administered for 3 days, with a maximum daily dose of 4 vials.",[15],[32],{"name":33,"affiliation":5,"role":34},"Yamei Tang","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":11,"email":40},"Xinguang Yang","CONTACT","86 + 13076822010","yangxinguang0926@163.com",[42],{"facility":43,"status":11,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University","Guangzhou","Guangdong","510120","China","CN",{"type":50,"coordinates":51},"Point",[52,53],113.25,23.11667,{"lat":53,"lon":52},[56,58],{"name":57,"role":38,"phone":11,"phoneExt":11,"email":40},"Xinguang Yang, MD",{"name":59,"role":34,"phone":11,"phoneExt":11,"email":11},"Yamei Tang, PhD",{"type":61,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100606445","methylprednisolone-sodium-succinate-with-endovascular-thrombectomy-for-large-ischemic-stroke-100606445",false,"NCT07175649","Methylprednisolone Sodium Succinate With Endovascular ThRombectomy for Large Ischemic STroke","Methylprednisolone Sodium Succinate With Endovascular ThRombectomy for Large Ischemic STroke: A Randomized, Double-blind, Placebo-controlled Trial","PEARL-MERIT","Inclusion Criteria:\n\n* Aged 18 to 85 years;\n* Clinically diagnosed acute ischemic stroke with screening NIHSS ≥6;\n* Time from last known well to randomization ≤24 hours;\n* Pre-stroke mRS score of 0-1;\n* Occlusion of the responsible vessel confirmed by CT angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA) in intracranial segment of internal carotid artery (ICA), M1 or M2 segment of middle cerebral artery (MCA), and plan to undergo EVT;\n* Alberta Stroke Program Early CT Score (ASPECTS) of 0-5 on NCCT, or ischemic core volume ≥70 mL (defined as regional cerebral blood flow \\[rCBF\\] \\\u003C30% on CT perfusion \\[CTP\\] or apparent diffusion coefficient \\[ADC\\] \\\u003C620×10-⁶ mm²\u002Fs on MRI);\n* Informed consent obtained.\n\nExclusion Criteria:\n\n* Intracranial hemorrhage on NCCT or MRI;\n* Allergy to corticosteroids;\n* Allergy to contrast agents;\n* Severe infectious disease unsuitable for corticosteroid therapy or concurrent contraindications to corticosteroid treatment;\n* Random blood glucose \\>22.2 mmol\u002FL (400 mg\u002FdL);\n* Known hereditary or acquired bleeding diathesis, coagulation factor deficiency, use of warfarin with an international normalized ratio (INR) \\>1.7, or administration of novel oral anticoagulants within 48 hours of symptom onset;\n* Platelet count \\\u003C90×10⁹\u002FL;\n* History of gastrointestinal or urinary tract bleeding within the last month;\n* Current participation in another interventional clinical trial;\n* Pregnancy or lactating;\n* Renal dysfunction with an estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin or serum creatinine \\>220 μmol\u002FL (2.5 mg\u002FdL);\n* Persistent systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg despite antihypertensive treatment;\n* Life expectancy \\\u003C6 months due to terminal illnesses such as malignancy or severe cardiopulmonary disease;\n* Intracranial aneurysm or arteriovenous malformation;\n* Intracranial tumour with mass effect on imaging (except for small meningiomas);\n* Other conditions deemed unsuitable for study participation by the investigator, including inability to comprehend and\u002For comply with study procedures and\u002For follow-up due to psychiatric, cognitive, or emotional disorders.","ALL","18 Years","85 Years",{"count":74,"type":75},912,"ESTIMATED","INTERVENTIONAL",[78],"NA","It is uncertain whether intravenous methylprednisolone improves outcomes for acute anterior circulation large vessel occlusion (LVO) patients with a large infarct core. In this study, the investigators hypothesize that methylprednisolone plus endovascular thrombectomy (EVT) might be superior to EVT alone in patients with evidence of a large infarct volume. The primary objective of the study is to establish the efficacy of methylprednisolone with EVT in patients with acute anterior circulation LVO and a large infarct core.",[81],"Ischemic Stroke, Acute","NOT_YET_RECRUITING","2025-09-09",{"date":85,"type":86},"2025-09-16","ACTUAL",{"date":88,"type":75},"2025-10",{"date":90,"type":75},"2029-12",{"name":5,"class":6},1]